Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pituitary gland

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: Pituitary gland. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-007036-95 Sponsor Protocol Number: CSOM230BDE01 Start Date*: 2008-07-02
    Sponsor Name:Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie
    Full Title: Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study
    Medical condition: Prolactinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036832 Prolactinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002877-30 Sponsor Protocol Number: CSOM230B2212 Start Date*: 2006-12-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning ad...
    Medical condition: duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning adenoma, TSH-adenoma,Gonadotroph adenoma, and PRL-adenoma)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035098 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010918-30 Sponsor Protocol Number: 2377 Start Date*: 2009-08-11
    Sponsor Name:Amar Agha, Beaumont Hospital
    Full Title: Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.
    Medical condition: 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021067 Hypopituitarism LLT
    9.1 10033662 Panhypopituitarism LLT
    9.1 10056438 Growth hormone deficiency LLT
    9.1 10011318 Craniopharyngioma LLT
    9.1 10036832 Prolactinoma LLT
    9.1 10011651 Cushing's disease LLT
    9.1 10035104 Pituitary tumour LLT
    9.1 10061538 Pituitary tumour benign LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000056-14 Sponsor Protocol Number: 06/DTD/3791E Start Date*: 2008-03-03
    Sponsor Name:Cardiff University
    Full Title: Determination of method-specific normal cortisol and adrenal hormone responses to the short Synacthen test
    Medical condition: Normal, healthy volunteers to establish a reference range for the synacthen test, plus patients with hypoadrenalism/hypopituitarism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020936 Hypoadrenalism LLT
    9.1 10021067 Hypopituitarism LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004413-15 Sponsor Protocol Number: CSOM230B2209 Start Date*: 2006-06-07
    Sponsor Name:Cedars Sinai Medical Center
    Full Title: Effectiveness of SOM230 In Treating Non-Functioning Pituitary Adenomas
    Medical condition: non-functioning pitiutary adenomes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035079 Pituitary adenoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002407-32 Sponsor Protocol Number: CSOM230B2208E1 Start Date*: 2004-10-21
    Sponsor Name:NOVARTIS FARMA
    Full Title: Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease
    Medical condition: Treatment of Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10035109 Pituitary-dependent Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000146-18 Sponsor Protocol Number: TM008 Start Date*: 2022-02-09
    Sponsor Name:Saniona A/S
    Full Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose finding, Multi-center, 36-week Safety and Efficacy Study with Open-label Extension Period of Tesomet in Subjects with Hypothalamic Obe...
    Medical condition: Hypothalamic Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004860 10013367 Disorders of the pituitary gland and its hypothalamic control LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024165-44 Sponsor Protocol Number: CSOM230B2406 Start Date*: 2011-08-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape)
    Medical condition: Cushing’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Prematurely Ended) ES (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001915-35 Sponsor Protocol Number: 08052017 Start Date*: 2017-09-15
    Sponsor Name:Medical University of Graz
    Full Title: GLUCOCORTICOID HIGH-DOSE VS. REPLACEMENT IN IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HYPOPHYSITIS: AN OPEN, RANDOMIZED PILOT STUDY
    Medical condition: Immune regulatory antibodies (e.g. ipilimumab, pembrolizumab and nivolumab) inhibiting immunological checkpoints are increasingly used to treat various oncological entities. Potential side effects ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002240-17 Sponsor Protocol Number: ATR-101-301 Start Date*: 2017-05-16
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome
    Medical condition: endogenous Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021008-77 Sponsor Protocol Number: PASIREOTIDE/01/2010 Start Date*: 2011-08-22
    Sponsor Name:Göteborgs Universitet, Göteborg Sweden
    Full Title: A MULTI - CENTER OPEN LABEL PHASE II (B) STUDY TO ASSESS EFFECTS OF SOM230 ON CARDIOVASCULAR PARAMETERS IN ACROMEGALIC PATIENTS
    Medical condition: Adult patients 18 to 80 years of age with diagnosed acromegaly eligible for treatment with a somatostatin analogue and not on previous pharmacological treatment for acromegaly.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005613-38 Sponsor Protocol Number: 44648368 Start Date*: 2006-05-31
    Sponsor Name:Dr. Chris Thompson
    Full Title: Assessment of platelet function in the hypopituitary population. Does hormone replacement therapy alter thrombotic risk?
    Medical condition: Hypopituitarism refers to decreased secretion of pituitary hormones, which can result from diseases of the pituitary gland or from diseases of the hypothalamus, which cause diminished secretion of ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005242-21 Sponsor Protocol Number: 07_ENDO_66 Start Date*: 2008-05-07
    Sponsor Name:THE CHRISTIE NHS FOUNDATION TRUST
    Full Title: A pilot study of replacement therapy with recombinant TSH in central hypothyroidism
    Medical condition: Central Hypothyroidism which is due to deficiency of TSH caused by the disease, surgery or radiotherapy of the pituitary gland.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004071-39 Sponsor Protocol Number: TOLV2012 Start Date*: 2012-10-16
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: Study on the effectiveness and safety of the treatment of mild-moderate symptomatic hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone (SIADH) with Tolvaptan vs fluid ...
    Medical condition: Mild-moderate symptomatic hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004468-69 Sponsor Protocol Number: TV1106-IMM-20001 Start Date*: 2014-06-11
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone (Genotropin®) Therapy in Treatment-Naive,...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    17.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) RO (Ongoing) GR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000737-31 Sponsor Protocol Number: OOC-ACM-303 Start Date*: 2017-10-27
    Sponsor Name:Chiasma, Inc.
    Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical c...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) PL (Completed) IT (Completed) BG (Completed) LV (Completed) SI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-003099-39 Sponsor Protocol Number: LWH0604 Start Date*: 2008-08-21
    Sponsor Name:Liverpool Women's NHS Foundation Trust Hospital
    Full Title: A Randomised Controlled Trial of Thyroxine in Preterm Infants Under 28 weeks' Gestation.
    Medical condition: Hypothyroidism is a condition where there is a lack of thyroid hormone in the body. Thyroid hormones are important for normal brain development and growth. Children who are born with low thyroid ho...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004802-24 Sponsor Protocol Number: NL68556.091.18 Start Date*: 2019-05-20
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia
    Medical condition: Congenital adrenal hyperplasia (CAH) is a disorder of adrenal steroid synthesis leading to cortisol deficiency and an increase in androgen production.Treatment in children consists of hydrocortis...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-000344-10 Sponsor Protocol Number: 06_ENDO_49 Start Date*: 2006-06-08
    Sponsor Name:Christie Hospital
    Full Title: Multi-centre study of cabergoline alone and in combination with pegvisomant in the management of active acromegaly
    Medical condition: acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:11:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA